Skip to content
01 Jun 2021

Topic: Cirrhosis and complications

Location: Digital

Meeting Type: EASL meetings


Decompensated cirrhosis affects over 10 million people worldwide and is the cause of mortality of about 2 million people yearly. Death rates remain largely unchanged, despite escalating healthcare costs. The clinical and prognostic models of decompensated cirrhosis have been studied extensively  in the past 20 years, leading up to the identification of a newly defined clinical entity: acute-on-chronic liver failure.

Emerging data from studies on the pathophysiological basis of decompensated cirrhosis has identified systemic inflammation as being central to the progression of liver disease and mortality. This new understanding is leading to rapid changes in the approaches to the management of cirrhotic patients, design of clinical trials, and selection of patients for early liver transplantation. In recognition of the exciting new developments in the field, EASL and the Journal of Hepatology have published a special Supplement summarising the current literature authored by leaders in the field. These two EASL webinars have been designed to allow the authors to critically discuss recent advances in decompensated cirrhosis with the audience. 

This second webinar will take place on 1 June 2021, 18:00–19:30 CET.

Learning objectives

  • Understand the changing epidemiology of cirrhosis
  • Learn about new perspectives in the trajectory of cirrhosis and why acute on chronic liver failure should be considered a distinct clinical entity
  • Understand the role of systemic inflammation and how this fits into the established pathophysiological mechanisms of decompensated cirrhosis
  • Understand how the management of decompensated cirrhosis is changing, the concept of disease modifying agents and issue of working beyond guidelines
  • Discover how sarcopenia and frailty impact on outcomes, their assessment and therapeutic approaches
  • Explore nuances in the intensive care management of patients with ACLF and the role of liver transplantation


Name  Affiliation   
Prof. Paolo Angeli  University of Padova  Chair 
Prof. Marina Berenguer  University of Valencia  Chair 
Dr. William Bernal  Kings College London  Speaker 
Prof. Raj Mookerjee  University College London  Speaker 
ProfPuneeta Tandon  University of Alberta  Speaker 
Prof. Patrizia Burra  University of Padova  Speaker 


Time Topic Speakers
18:00 – 18:05 Welcome and Introduction Paolo Angeli / Marina Berenguer
18:05 – 18:20 Intensive Care Management William Bernal
18:20 – 18:35 Established and Novel therapies for decompensated cirrhosis Raj Mookerjee
18:35 – 18:50 Assessment and management of  Sarcopenia and Frailty Puneeta Tandon
18:50 – 19:05 Changing rules for transplanting patients with decompensated cirrhosis Patrizia Burra
19:05 – 19:30 Discussion and Q&A All

Journal of Hepatology Supplement

Publication of the supplement was supported financially by CSL Behring. The sponsor had no involvement in content development, the decision to submit the manuscript or in the acceptance of the manuscript for publication.

Liver Transplantation at ILC 2021

Liver Transplantation and Surgery will be given a special emphasis at ILC 2021.

See the Liver Transplantation sessions at ILC 2021.

Cirrhosis & Complications at ILC 2021

At ILC 2021, this track presents an overview of the role of vessels in liver diseases. The track content will include not only the role of liver sinusoidal changes in liver disease progression, but also the management of portal and hepatic vein thrombosis and their complications. The management of complications of portal hypertension will also be addressed, including the place of transjugular intrahepatic portosystemic shunt (TIPS) and the management of patients with advanced cirrhosis and acute-on-chronic liver failure (ACLF).

See the Cirrhosis & Complications sessions at ILC 2021

Back To Top